These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23088972)

  • 1. Nitric oxide synthase (eNOS4a/b) gene polymorphism is associated with tumor recurrence and progression in superficial bladder cancer cases.
    Amasyali AS; Kucukgergin C; Erdem S; Sanli O; Seckin S; Nane I
    J Urol; 2012 Dec; 188(6):2398-403. PubMed ID: 23088972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer.
    Ito M; Habuchi T; Watanabe J; Higashi S; Nishiyama H; Wang L; Tsuchiya N; Kamoto T; Ogawa O
    Urology; 2004 Jul; 64(1):74-8. PubMed ID: 15245939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the T-786C, G894T, and Intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer.
    Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S
    Urol Oncol; 2013 Oct; 31(7):1132-40. PubMed ID: 22317880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
    Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
    Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer.
    Kim EJ; Jeong P; Quan C; Kim J; Bae SC; Yoon SJ; Kang JW; Lee SC; Jun Wee J; Kim WJ
    Urology; 2005 Jan; 65(1):70-5. PubMed ID: 15667866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer.
    Salinas-Sánchez AS; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-del-Campo A; Gimenez-Bachs JM; Lorenzo-Romero JG; Serrano-Oviedo L; Escribano J
    BJU Int; 2011 Jun; 107(11):1825-32. PubMed ID: 20942828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes.
    Ryk C; Koskela LR; Thiel T; Wiklund NP; Steineck G; Schumacher MC; de Verdier PJ
    Redox Biol; 2015 Dec; 6():272-277. PubMed ID: 26298202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
    Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
    Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 Gene mutations in superficial bladder cancer.
    Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
    Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial nitric oxide synthase gene intron4 VNTR polymorphism in patients with chronic kidney disease.
    Elshamaa MF; Sabry S; Badr A; El-Ahmady M; Elghoroury EA; Thabet EH; Kandil D; Kamel S
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):487-92. PubMed ID: 21519233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7.
    Medeiros RM; Morais A; Vasconcelos A; Costa S; Pinto D; Oliveira J; Ferreira P; Lopes C
    Clin Cancer Res; 2002 Nov; 8(11):3433-7. PubMed ID: 12429631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of nitric oxide synthase Glu298Asp polymorphism on the development of end-stage renal disease in type 2 diabetic Egyptian patients.
    El-Din Bessa SS; Hamdy SM
    Ren Fail; 2011; 33(9):878-84. PubMed ID: 21854353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based case-control study of the Arg399Gln polymorphism in DNA repair gene XRCC1 and risk of breast cancer.
    Shu XO; Cai Q; Gao YT; Wen W; Jin F; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1462-7. PubMed ID: 14693738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility.
    Tasci AI; Tugcu V; Ozbek E; Ozbay B; Simsek A; Koksal V
    BJU Int; 2008 Feb; 101(4):503-7. PubMed ID: 17986285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma total nitric oxide and endothelial constitutive nitric oxide synthase (ecNOS) gene polymorphism: a study in a South Indian population.
    Gururajan P; Gurumurthy P; Victor D; Srinivasa Nageswara Rao G; Sai Babu R; Sarasa Bharati A; Cherian KM
    Biochem Genet; 2011 Feb; 49(1-2):96-103. PubMed ID: 21069449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene.
    Safarinejad MR; Shafiei N; Safarinejad SH
    Arch Toxicol; 2011 Oct; 85(10):1209-18. PubMed ID: 21347663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.